{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T08:35:22Z","timestamp":1771922122669,"version":"3.50.1"},"reference-count":75,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Currently, we are at an enviable place in hemophilia treatment. Although full prophylaxis with standard half-life recombinant or plasma-derived factor concentrates has been definitively shown to be inadequate for full protection against bleeding and arthropathy, a number of novel therapies with improved hemostatic enhancement are clinically available or in promising clinical trials. In order to compare outcomes among a number of very efficacious therapies, it is necessary to have sensitive tools employed in long-term follow-up for several years for participants with no or minimal joint disease. The tool kit must be comprehensive, with outcomes of bleeding, factor level restoration or hemostatic capacity, joint structure, joint function, pain, quality of life, and patient satisfaction. This article reviews the history of prophylaxis, the promise of emerging therapies, and the sensitive tools used to assess long-term efficacy for joint structure and function.<\/jats:p>","DOI":"10.1182\/hematology.2022000397","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:13:36Z","timestamp":1670602416000},"page":"579-585","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Long-term prophylaxis: what are our options and how to define success?"],"prefix":"10.1182","volume":"2022","author":[{"given":"Marilyn Jean","family":"Manco-Johnson","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Hemophilia and Thrombosis Center, University of Colorado, Anschutz Medical Campus, Aurora, CO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth Boulden","family":"Warren","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hemophilia and Thrombosis Center, University of Colorado, Anschutz Medical Campus, Aurora, CO"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"4","key":"2022120916095829400_hem2022000397C1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2796.1994.tb00815.x","article-title":"A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group","volume":"236","author":"Aledort","year":"1994","journal-title":"J Intern Med"},{"issue":"5","key":"2022120916095829400_hem2022000397C2","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1046\/j.1365-2516.1999.00338.x","article-title":"Prevalence and incidence of intracranial haemorrhage in a population of children with haemophilia. The Hemophilia Growth and Development Study","volume":"5","author":"Nelson","year":"1999","journal-title":"Haemophilia"},{"issue":"suppl 3","key":"2022120916095829400_hem2022000397C3","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1007\/PL00014346","article-title":"Prevalence and outcome of intracranial haemorrhage in haemophiliacs \u2014a survey of the paediatric group of the German Society of Thrombosis and Haemostasis (GTH)","volume":"158","author":"Klinge","year":"1999","journal-title":"Eur J Pediatr"},{"issue":"1","key":"2022120916095829400_hem2022000397C4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2796.1992.tb00546.x","article-title":"Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B","volume":"232","author":"Nilsson","year":"1992","journal-title":"J Intern Med"},{"issue":"6","key":"2022120916095829400_hem2022000397C5","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"issue":"11","key":"2022120916095829400_hem2022000397C6","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/bloodadvances.2019001311","article-title":"Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study","volume":"4","author":"Warren","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"2022120916095829400_hem2022000397C7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1046\/j.1365-2516.1998.440413.x","article-title":"When should prophylactic treatment in patients with haemophilia A and B start?\u2014the German experience","volume":"4","author":"Kreuz","year":"1998","journal-title":"Haemophilia"},{"issue":"5","key":"2022120916095829400_hem2022000397C8","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/hae.13778","article-title":"Factor VIII prophylaxis effects outweigh other hemostasis contributors in predicting severe haemophilia A joint outcomes","volume":"25","author":"Warren","year":"2019","journal-title":"Haemophilia"},{"issue":"2","key":"2022120916095829400_hem2022000397C9","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2011-07-360594","article-title":"Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight","volume":"119","author":"Bj\u00f6rkman","year":"2012","journal-title":"Blood"},{"issue":"June","key":"2022120916095829400_hem2022000397C10","doi-asserted-by":"crossref","first-page":"103678","DOI":"10.1016\/j.critrevonc.2022.103678","article-title":"Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: a critical review from the physician's perspective","volume":"174","author":"Hermans","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"13","key":"2022120916095829400_hem2022000397C11","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood.2020005673","article-title":"Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study","volume":"137","author":"Klamroth","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2022120916095829400_hem2022000397C12","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","article-title":"Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A","volume":"126","author":"Konkle","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2022120916095829400_hem2022000397C13","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A","volume":"123","author":"Mahlangu","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2022120916095829400_hem2022000397C14","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/jth.12911","article-title":"Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A","volume":"13","author":"Young","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2022120916095829400_hem2022000397C15","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/hae.14576","article-title":"Clinical application of extended half-life factor VIII in children with severe haemophilia A","volume":"28","author":"Dettoraki","year":"2022","journal-title":"Haemophilia"},{"issue":"11","key":"2022120916095829400_hem2022000397C16","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa2002699","article-title":"BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A","volume":"383","author":"Konkle","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"2022120916095829400_hem2022000397C17","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","article-title":"Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B","volume":"369","author":"Powell","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"2022120916095829400_hem2022000397C18","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/S2352-3026(16)30193-4","article-title":"Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study","volume":"4","author":"Fischer","year":"2017","journal-title":"Lancet Haematol"},{"issue":"12","key":"2022120916095829400_hem2022000397C19","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1182\/blood-2012-05-429688","article-title":"Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients","volume":"120","author":"Santagostino","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2022120916095829400_hem2022000397C20","first-page":"659","article-title":"Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial","volume":"116","author":"Kenet","year":"2016","journal-title":"Thromb Haemost"},{"issue":"26","key":"2022120916095829400_hem2022000397C21","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/blood-2014-05-573055","article-title":"Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial","volume":"124","author":"Collins","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2022120916095829400_hem2022000397C22","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/jth.13360","article-title":"Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial","volume":"14","author":"Carcao","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2022120916095829400_hem2022000397C23","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/hae.14018","article-title":"High adherence to prophylaxis regimens in haemophilia B patients receiving rIX-FP: evidence from clinical trials and real-world practice","volume":"26","author":"Mancuso","year":"2020","journal-title":"Haemophilia"},{"issue":"5","key":"2022120916095829400_hem2022000397C24","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1586\/17474086.2014.951322","article-title":"Alprolix (recombinant factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B","volume":"7","author":"Ducore","year":"2014","journal-title":"Expert Rev Hematol"},{"issue":"16","key":"2022120916095829400_hem2022000397C25","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with\/without FVIII inhibitors from the HAVEN 1-4 studies","volume":"37","author":"Callaghan","year":"2020","journal-title":"Blood"},{"key":"2022120916095829400_hem2022000397C26","unstructured":"Clinicaltrials.gov. A study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous emicizumab in participants from birth to 12 months of age with hemophilia a without inhibitors (HAVEN 7). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04431726. Accessed 28October2022."},{"issue":"6","key":"2022120916095829400_hem2022000397C27","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/jth.15682","article-title":"A novel next-generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: results from safety studies in cynomolgus monkeys","volume":"20","author":"Lauritzen","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2022120916095829400_hem2022000397C28","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.ymthe.2019.11.006","article-title":"A molecular revolution in the treatment of hemophilia","volume":"28","author":"Butterfield","year":"2020","journal-title":"Mol Ther"},{"issue":"5","key":"2022120916095829400_hem2022000397C29","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/blood-2018-08-872291","article-title":"New therapies for hemophilia","volume":"133","author":"Weyand","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2022120916095829400_hem2022000397C30","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1616569","article-title":"Targeting of antithrombin in hemophilia A or B with RNAi therapy","volume":"377","author":"Pasi","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"2022120916095829400_hem2022000397C31","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1182\/blood.2019001542","article-title":"Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A\/B with inhibitors: phase 2 trial results","volume":"134","author":"Shapiro","year":"2019","journal-title":"Blood"},{"key":"2022120916095829400_hem2022000397C32","article-title":"A phase 1b\/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia [published online 23 August 2022]","author":"Mahlangu","journal-title":"Br J Haematol"},{"issue":"1","key":"2022120916095829400_hem2022000397C33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N Engl J Med"},{"issue":"23","key":"2022120916095829400_hem2022000397C34","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N Engl J Med"},{"issue":"21","key":"2022120916095829400_hem2022000397C35","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/bloodadvances.2019000811","article-title":"Etranacogene dezaparvovec (AMT-061 phase 2b): normal\/near normal FIX activity and bleed cessation in hemophilia B","volume":"3","author":"Von Drygalski","year":"2019","journal-title":"Blood Adv"},{"issue":"23","key":"2022120916095829400_hem2022000397C36","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","volume":"130","author":"Lenting","year":"2017","journal-title":"Blood"},{"issue":"suppl 3","key":"2022120916095829400_hem2022000397C37","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/hae.14099","article-title":"Outcome measures in haemophilia: beyond ABR (annualized bleeding rate)","volume":"27","author":"Manco-Johnson","year":"2021","journal-title":"Haemophilia"},{"issue":"4","key":"2022120916095829400_hem2022000397C38","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1365-2516.2008.01689.x","article-title":"Experimental haemophilic arthropathy in a mouse model of a massive haemarthrosis: gross, radiological and histological changes","volume":"14","author":"Hakobyan","year":"2008","journal-title":"Haemophilia"},{"issue":"5","key":"2022120916095829400_hem2022000397C39","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1046\/j.1365-2796.1997.130135000.x","article-title":"Haemophilia prophylaxis in young patients\u2014a long-term follow-up","volume":"241","author":"L\u00f6fqvist","year":"1997","journal-title":"J Intern Med"},{"key":"2022120916095829400_hem2022000397C40","unstructured":"International Prophylaxis Study Group. Group IPSGP. Hemophilia Joint Health Score (HJHS) 2.1 Instruction Manual. World Federation of Hemophilia; 2012. https:\/\/elearning.wfh.org\/resource\/hemophilia-joint-health-score-hjhs\/. Accessed 28October2022."},{"issue":"suppl 4","key":"2022120916095829400_hem2022000397C41","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1365-2516.2004.00978.x","article-title":"Physical therapy and imaging outcome measures in a haemophilia population treated with factor prophylaxis: current status and future directions","volume":"10","author":"Manco-Johnson","year":"2004","journal-title":"Haemophilia"},{"issue":"1","key":"2022120916095829400_hem2022000397C42","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2516.2006.01387.x","article-title":"The Colorado Haemophilia Paediatric Joint Physical Examination Scale: normal values and interrater reliability","volume":"13","author":"Hacker","year":"2007","journal-title":"Haemophilia"},{"issue":"3","key":"2022120916095829400_hem2022000397C43","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1046\/j.1365-2516.2000.00383.x","article-title":"MRI findings in haemophilic joints treated with radiosynoviorthesis with development of an MRI scale of joint damage","volume":"6","author":"Nuss","year":"2000","journal-title":"Haemophilia"},{"issue":"suppl 3","key":"2022120916095829400_hem2022000397C44","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1365-2516.2008.01750.x","article-title":"Musculoskeletal measurement tools from the International Prophylaxis Study Group (IPSG)","volume":"14","author":"Feldman","year":"2008","journal-title":"Haemophilia"},{"issue":"6","key":"2022120916095829400_hem2022000397C45","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/j.1365-2516.2012.02883.x","article-title":"An MRI scale for assessment of haemophilic arthropathy from the International Prophylaxis Study Group","volume":"18","author":"Lundin","year":"2012","journal-title":"Haemophilia"},{"issue":"2","key":"2022120916095829400_hem2022000397C46","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/acr.20353","article-title":"Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: validity of the Hemophilia Joint Health Score","volume":"63","author":"Feldman","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"2022120916095829400_hem2022000397C47","doi-asserted-by":"crossref","first-page":"e12690","DOI":"10.1002\/rth2.12690","article-title":"The Hemophilia Joint Health Score version 2.1 Validation in Adult Patients Study: a multicenter international study","volume":"6","author":"St-Louis","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"suppl 1","key":"2022120916095829400_hem2022000397C48","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1182\/blood-2021-151532","article-title":"Early findings on the use of motion capture during simulated sports activities to better understand hemophilic arthropathy","volume":"138","author":"Warren","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2022120916095829400_hem2022000397C49","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3390\/hematolrep14020017","article-title":"Biomechanical gait analysis of an adult with severe hemophilia: a case report","volume":"14","author":"Fukuchi","year":"2022","journal-title":"Hematol Rep"},{"issue":"6","key":"2022120916095829400_hem2022000397C50","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1160\/TH12-11-0874","article-title":"Development and definition of a simplified scanning procedure and scoring method for Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US)","volume":"109","author":"Martinoli","year":"2013","journal-title":"Thromb Haemost"},{"issue":"5","key":"2022120916095829400_hem2022000397C51","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/hae.14368","article-title":"Quantitative measurements of haemophilic joint tissues by point-of-care musculoskeletal ultrasound: associations with clinical and functional joint outcome parameters","volume":"27","author":"Mesleh Shayeb","year":"2021","journal-title":"Haemophilia"},{"issue":"4","key":"2022120916095829400_hem2022000397C52","doi-asserted-by":"crossref","first-page":"e0248952","DOI":"10.1371\/journal.pone.0248952","article-title":"Correlation between Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) score and Hemophilia Joint Health Score (HJHS) in patients with hemophilic arthropathy","volume":"16","author":"Prasetyo","year":"2021","journal-title":"Plos One"},{"issue":"6","key":"2022120916095829400_hem2022000397C53","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/MBC.0000000000000934","article-title":"HJHS 2.1 and HEAD-US assessment in the hemophilic joints: how do their findings compare?","volume":"31","author":"De la Corte-Rodriguez","year":"2020","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"2","key":"2022120916095829400_hem2022000397C54","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/hae.12792","article-title":"Early prophylaxis in children with severe haemophilia A: clinical and ultrasound imaging outcomes","volume":"22","author":"Altisent","year":"2016","journal-title":"Haemophilia"},{"issue":"3","key":"2022120916095829400_hem2022000397C55","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/hae.12667","article-title":"Differentiating between signs of intra-articular joint bleeding and chronic arthropathy in haemophilia: a narrative review of the literature","volume":"21","author":"Timmer","year":"2015","journal-title":"Haemophilia"},{"issue":"5","key":"2022120916095829400_hem2022000397C56","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/hae.12175","article-title":"Rapid musculoskeletal ultrasound for painful episodes in adult haemophilia patients","volume":"19","author":"Ceponis","year":"2013","journal-title":"Haemophilia"},{"issue":"6846","key":"2022120916095829400_hem2022000397C57","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/bmj.305.6846.160","article-title":"Validating the SF-36 health survey questionnaire: new outcome measure for primary care","volume":"305","author":"Brazier","year":"1992","journal-title":"BMJ"},{"issue":"suppl 5, pt 39","key":"2022120916095829400_hem2022000397C58","first-page":"S53","article-title":"The promise of PROMIS: using item response theory to improve assessment of patient-reported outcomes","volume":"23","author":"Fries","year":"2005","journal-title":"Clin Exp Rheumatol"},{"issue":"suppl 1, pt 5","key":"2022120916095829400_hem2022000397C59","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.mlr.0000258615.42478.55","article-title":"The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years","volume":"45","author":"Cella","year":"2007","journal-title":"Med Care"},{"issue":"1","key":"2022120916095829400_hem2022000397C60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0304-3959(87)91056-6","article-title":"The Varni\/Thompson Pediatric Pain Questionnaire, I: Chronic musculoskeletal pain in juvenile rheumatoid arthritis","volume":"28","author":"Varni","year":"1987","journal-title":"Pain"},{"issue":"8","key":"2022120916095829400_hem2022000397C61","doi-asserted-by":"crossref","first-page":"e021900","DOI":"10.1136\/bmjopen-2018-021900","article-title":"Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire","volume":"8","author":"Chai-Adisaksopha","year":"2018","journal-title":"BMJ Open"},{"issue":"3","key":"2022120916095829400_hem2022000397C62","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/rth2.12498","article-title":"Updating the Canadian Hemophilia Outcomes-Kids' Life Assessment Tool (CHO-KLAT) in the era of extended half-life clotting factor concentrates","volume":"5","author":"Price","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"2022120916095829400_hem2022000397C63","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2147\/PPA.S87659","article-title":"Associations of quality of life, pain, and self-reported arthritis with age, employment, bleed rate, and utilization of hemophilia treatment center and health care provider services: results in adults with hemophilia in the HERO study","volume":"9","author":"Forsyth","year":"2015","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"2022120916095829400_hem2022000397C64","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0304-3959(87)90161-8","article-title":"Acute and chronic pain in hemophilia","volume":"31","author":"Choini\u00e8re","year":"1987","journal-title":"Pain"},{"issue":"suppl 1","key":"2022120916095829400_hem2022000397C65","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/ejh.13027","article-title":"Assessments of pain, functional impairment, anxiety, and depression in US adults with hemophilia across patient-reported outcome instruments in the Pain, Functional Impairment, and Quality of Life (P-FiQ) study","volume":"100","author":"Buckner","year":"2018","journal-title":"Eur J Haematol"},{"issue":"3","key":"2022120916095829400_hem2022000397C66","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/hae.12597","article-title":"International cross-cultural validation study of the Canadian Haemophilia Outcomes: Kids' Life Assessment Tool","volume":"21","author":"McCusker","year":"2015","journal-title":"Haemophilia"},{"issue":"1","key":"2022120916095829400_hem2022000397C67","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/hae.14187","article-title":"Validation of a new instrument to measure disease-related distress among patients with haemophilia","volume":"27","author":"Kempton","year":"2021","journal-title":"Haemophilia"},{"issue":"1","key":"2022120916095829400_hem2022000397C68","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1055\/s-0038-1624568","article-title":"Sociodemographic, clinical, and psychosocial characteristics of people with hemophilia in Portugal: findings from the First National Survey","volume":"2","author":"Pinto","year":"2018","journal-title":"TH Open"},{"key":"2022120916095829400_hem2022000397C69","first-page":"58","volume":"4","author":"Skinner","year":"2018"},{"issue":"6","key":"2022120916095829400_hem2022000397C70","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1111\/hae.14036","article-title":"Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: results from the B-YOND extension study","volume":"26","author":"Pasi","year":"2020","journal-title":"Haemophilia"},{"issue":"11","key":"2022120916095829400_hem2022000397C71","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N Engl J Med"},{"issue":"21","key":"2022120916095829400_hem2022000397C72","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","article-title":"Multiyear factor VIII expression after AAV gene transfer for hemophilia A","volume":"385","author":"George","year":"2021","journal-title":"N Engl J Med"},{"key":"2022120916095829400_hem2022000397C73","first-page":"99","article-title":"Final analysis from the pivotal phase 3 HOPE-B gene therapy trial: stable steady-state efficacy and safety of etranacogene dezaparvovec in adults with severe or moderately severe hemophilia B [abstract]","volume":"28","author":"Miesbach","year":"2022","journal-title":"Haemophilia"},{"issue":"21","key":"2022120916095829400_hem2022000397C74","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"2022120916095829400_hem2022000397C75","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJMoa2119913","article-title":"Phase 1\u20132 trial of AAVS3 gene therapy in patients with hemophilia B","volume":"387","author":"Chowdary","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/579\/2021978\/579mancojohnson.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/579\/2021978\/579mancojohnson.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:14:15Z","timestamp":1670602455000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2022\/1\/579\/493522\/Long-term-prophylaxis-what-are-our-options-and-how"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,9]]},"published-print":{"date-parts":[[2022,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2022000397","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,9]]},"published":{"date-parts":[[2022,12,9]]}}}